J. Yates, H. Wallace, . Jr, R. Ellison, and J. Holland, Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia, Cancer Chemother Rep, vol.57, issue.4, pp.485-488, 1973.

H. Preisler, Y. Rustum, and E. Henderson, Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens, Blood, vol.53, issue.3, pp.455-464, 1979.

A. Burnett, M. Wetzler, and L. ¨. , Therapeutic Advances in Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.29, issue.5, pp.487-494, 2011.
DOI : 10.1200/JCO.2010.30.1820

J. Rowe, Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?, Best Practice & Research Clinical Haematology, vol.22, issue.4, pp.509-515, 2009.
DOI : 10.1016/j.beha.2009.10.003

L. , B. Ossenkoppele, G. Van-putten, and W. , Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia [published correction appears in, N Engl J Med. N Engl J Med, vol.362361, issue.1213, pp.1155-1235, 2009.

K. Bradstock, E. Link, and M. Collins, A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia, British Journal of Haematology, vol.60, issue.5, pp.618-625, 2014.
DOI : 10.1182/blood-2002-04-1199

J. Weick, K. Kopecky, and F. Appelbaum, A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study, Blood, vol.88, issue.8, pp.2841-2851, 1996.

L. , B. Pabst, T. Vellenga, and E. , Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia, N Engl J Med, vol.364, issue.11, pp.1027-1036, 2011.

J. Zeidner, M. Foster, and A. Blackford, Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia, Haematologica, vol.100, issue.9, pp.1172-1179, 2015.
DOI : 10.3324/haematol.2015.125849

R. Mawad, P. Becker, and P. Hendrie, Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS, British Journal of Haematology, vol.2004, issue.2, pp.238-245, 2016.
DOI : 10.1182/asheducation-2004.1.98

D. ¨-ohner, H. Estey, E. Amadori, and S. , Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-474, 2010.

G. Marcucci, T. Haferlach, D. ¨. , and H. , Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications, Journal of Clinical Oncology, vol.29, issue.5, pp.475-486, 2011.
DOI : 10.1200/JCO.2010.30.2554

J. Ciccolini, DPD deficiency in patients treated with fluorouracil, The Lancet Oncology, vol.16, issue.16, pp.1574-1576, 2015.
DOI : 10.1016/S1470-2045(15)00360-5

D. Meulendijks, A. Cats, J. Beijnen, and J. Schellens, Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity ??? Ready for clinical practice?, Cancer Treatment Reviews, vol.50, pp.23-34, 2016.
DOI : 10.1016/j.ctrv.2016.08.002

J. Ciccolini, E. Gross, L. Dahan, B. Lacarelle, and C. Mercier, Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil???Related Severe Toxicities: Hype or Hope?, Clinical Colorectal Cancer, vol.9, issue.4, pp.224-228, 2010.
DOI : 10.3816/CCC.2010.n.033

C. Serdjebi, G. Milano, and J. Ciccolini, Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs, Expert Opinion on Drug Metabolism & Toxicology, vol.125, issue.12, pp.665-672, 2015.
DOI : 10.1007/s00228-010-0859-5

S. Cohen, The lethality of aranucleotides, Med Biol, vol.54, issue.5, pp.299-326, 1976.

J. Ciccolini, C. Serdjebi, L. T. Thu, H. Lacarelle, B. Milano et al., Nucleoside analogs: ready to enter the era of precision medicine?, Expert Opinion on Drug Metabolism & Toxicology, vol.46, issue.9, pp.865-877, 2016.
DOI : 10.1179/joc.2010.22.2.129

J. Ciccolini, L. Dahan, and N. Andréandr´andré, Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies, Journal of Clinical Oncology, vol.28, issue.1, pp.160-165, 2010.
DOI : 10.1200/JCO.2009.24.4491

J. Ciccolini, C. Mercier, L. Dahan, and N. Andréandr´andré, Integrating pharmacogenetics into gemcitabine dosing???time for a change?, Nature Reviews Clinical Oncology, vol.9, issue.7, pp.439-444, 2011.
DOI : 10.3816/CCC.2010.n.033

G. Peters, R. Honeywell, and M. Maulandi, EORTC-Pharmacology and Molecular Mechanism Group. Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment, Nucleosides Nucleotides Nucleic Acids, vol.33, pp.4-6, 2014.

R. Fanciullino, C. Mercier, and C. Serdjebi, Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale, Pharmacogenomics, vol.73, issue.2, pp.1907-1912, 2015.
DOI : 10.1517/14656566.2014.936849

T. Ohta, H. Hori, and M. Ogawa, Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells, Oncology Reports, vol.12, issue.5, pp.1115-1120, 2004.
DOI : 10.3892/or.12.5.1115

J. Ciccolini, A. Evrard, M. Batchi, and L. , CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations, Pharmacogenomics, vol.3, issue.4, pp.393-397, 2012.
DOI : 10.1200/JCO.2009.27.4928
URL : https://hal.archives-ouvertes.fr/hal-01707696

C. Tibaldi, E. Giovannetti, and M. Tiseo, Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients, Annals of Oncology, vol.16, issue.3, pp.670-677, 2012.
DOI : 10.1038/nrclinonc.2011.1

E. Giovannetti, A. Laan, and E. Vasile, Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples, Nucleosides, Nucleotides and Nucleic Acids, vol.26, issue.6-7, pp.720-725, 2008.
DOI : 10.1126/science.286.5439.487

H. Haupt, G. Hutchins, and G. Moore, Ara-C lung: Noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia, The American Journal of Medicine, vol.70, issue.2, pp.256-261, 1981.
DOI : 10.1016/0002-9343(81)90759-2

C. Mercier, C. Raynal, and L. Dahan, Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation, Pharmacogenetics and Genomics, vol.17, issue.10, pp.841-844, 2007.
DOI : 10.1097/FPC.0b013e32825ea6e3

K. Yonemori, H. Ueno, and T. Okusaka, Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin, Clinical Cancer Research, vol.11, issue.7, pp.2620-2624, 2005.
DOI : 10.1158/1078-0432.CCR-04-1497

E. Moreau, N. Andréandr´andré, C. Coze, L. Padovani, C. Mercier et al., Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine? Pediatr Blood Cancer, pp.781-782, 2010.

W. Van-der-velden, A. Herbers, M. Netea, and N. Blijlevens, Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis, British Journal of Haematology, vol.8, issue.Suppl. 1, pp.441-452, 2014.
DOI : 10.1038/nri2216

C. Mercier, A. Evrard, and J. Ciccolini, Genotype-Based Methods for Anticipating Gemcitabine-Related Severe Toxicities May Lead to False-Negative Results, Journal of Clinical Oncology, vol.25, issue.30, pp.4855-4855, 2007.
DOI : 10.1200/JCO.2007.13.3918

E. Giovannetti, C. Tibaldi, A. Falcone, R. Danesi, and G. Peters, Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing, Journal of Clinical Oncology, vol.28, issue.14, pp.221-222, 2010.
DOI : 10.1200/JCO.2009.27.4928

A. Evrard, B. Lacarelle, and J. Ciccolini, Severe or lethal toxicities with nucleosidic analogs: time for action, Pharmacogenomics, vol.28, issue.3, pp.227-230, 2013.
DOI : 10.1007/s00439-006-0142-0

C. Serdjebi, F. Gattacceca, and J. Seitz, Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach, Therapeutic Drug Monitoring, vol.39, issue.3, pp.290-296, 2017.
DOI : 10.1097/FTD.0000000000000399

T. Bosch, I. Meijerman, J. Beijnen, and J. Schellens, Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer, Clinical Pharmacokinetics, vol.5, issue.2, pp.253-285, 2006.
DOI : 10.2165/00003088-200645030-00003

S. Gemble, G. Buhagiar-labarchèdelabarch-`-labarchède, R. Onclercq-delic, C. Jaulin, and M. Amor-gú-eret, Cytidine deaminase deficiency impairs sister chromatid disjunction by decreasing PARP-1 activity, Cell Cycle, vol.15, issue.11, pp.1128-1135, 2017.
DOI : 10.1038/ncomms9962
URL : https://hal.archives-ouvertes.fr/hal-01559255